Clinical Trial Update: A Study of Paclitaxel With or Without Ramucirumab (IMC-1211B) in Metastatic Gastric Adenocarcinoma [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating paclitaxel with or without ramucirumab (IMC-1211B) in metastatic gastric adenocarcinoma has completed and results were posted in 2014.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastric Adenocarcinoma
• Gastric Cancer

Drugs mentioned

• PACLITAXEL (PACLITAXEL)
• Ramucirumab (ramucirumab)

Snippet

Sponsor: Eli Lilly and Company | Conditions: Gastric Cancer | Phase 3 | Status: COMPLETED | Results posted: 2014-07-31